March 17, 2020 10:26 AM EDT
News Briefing

Rick Klaus­ner's Lyell part­ners, helps fund Eu­reka's work on cell ther­a­pies; Blue­print bounces high­er on PhII

ENDPOINTS

→ Lyell chief Rick Klaus­ner con­tin­ues to build up his net­work of com­pa­nies beaver­ing away at new cell ther­a­pies. The Glax­o­SmithK­line part­ner led a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times